Cybin Inc. (NASDAQ:HELP) Given Average Recommendation of "Buy" by Brokerages

Key Points

• Analysts have an average recommendation of "Buy" on Cybin (6 analysts: 5 buys, 1 strong buy) with a mean 1-year price target of $58.75, though individual targets vary widely (e.g., HC Wainwright $95, Jefferies $22).
• Shares traded at $5.42 (up 3.7% on the day) with a market cap of about $279.6 million, a one‑year range of $4.29–$9.83, and a negative PE of -1.28.
• Cybin is a clinical‑stage psychedelics-focused biopharma that reported a Q loss of ($0.72) EPS (missing the ($0.53) estimate), while institutional ownership stands at about 17.94% after notable buying by firms including Millennium Management.

Shares of Cybin Inc. (NASDAQ:HELP - Get Free Report) have been assigned an average recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $58.75.

HELP has been the topic of several analyst reports. Jefferies Financial Group initiated coverage on Cybin in a report on Monday, February 2nd. They issued a "buy" rating and a $22.00 target price on the stock. HC Wainwright upped their target price on Cybin from $55.00 to $95.00 and gave the company a "buy" rating in a report on Monday, March 2nd. Finally, TD Cowen initiated coverage on Cybin in a report on Monday. They issued a "buy" rating on the stock.

Cybin Stock Up 3.7%

NASDAQ:HELP traded up $0.20 during trading hours on Monday, hitting $5.42. 195,547 shares of the company were exchanged, compared to its average volume of 758,857. The business's fifty day moving average is $5.84. Cybin has a one year low of $4.29 and a one year high of $9.83. The company has a market cap of $279.58 million, a PE ratio of -1.28 and a beta of 0.77.

Cybin (NASDAQ:HELP - Get Free Report) last announced its earnings results on Friday, February 13th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.19).

Institutional Trading of Cybin

Several institutional investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. boosted its holdings in shares of Cybin by 46.7% during the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company's stock worth $63,000 after buying an additional 2,400 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Cybin by 66.8% during the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company's stock worth $247,000 after buying an additional 11,790 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of Cybin by 1,388.5% during the 4th quarter. Millennium Management LLC now owns 1,028,549 shares of the company's stock worth $8,414,000 after buying an additional 959,448 shares in the last quarter. 17.94% of the stock is currently owned by institutional investors.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.